There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Alnylam Pharma (ALNY – Research Report), IDEAYA Biosciences (IDYA – Research Report) and Surgery Partners (SGRY – Research Report) with bullish sentiments.
Alnylam Pharma (ALNY)
RBC Capital analyst Luca Issi maintained a Buy rating on Alnylam Pharma today and set a price target of $235.00. The company’s shares closed last Tuesday at $198.20.
According to TipRanks.com, Issi is ranked 0 out of 5 stars with an average return of
Alnylam Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $229.41, implying a 16.6% upside from current levels. In a report issued on January 2, Bernstein also maintained a Buy rating on the stock with a $220.00 price target.
See the top stocks recommended by analysts >>
IDEAYA Biosciences (IDYA)
In a report released today, Gregory Renza from RBC Capital maintained a Buy rating on IDEAYA Biosciences, with a price target of $43.00. The company’s shares closed last Tuesday at $35.89, close to its 52-week high of $36.68.
According to TipRanks.com, Renza is a 5-star analyst with an average return of
IDEAYA Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $41.43.
Surgery Partners (SGRY)
In a report released today, Bill Sutherland from Benchmark Co. reiterated a Buy rating on Surgery Partners, with a price target of $50.00. The company’s shares closed last Tuesday at $33.28.
According to TipRanks.com, Sutherland has 0 stars on 0-5 stars ranking scale with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Surgery Partners with a $43.00 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ALNY:
- Alnylam price target raised to $237 from $233 at Citi
- Alnylam reports preliminary Q4, FY23 global net product revenues
- The Smid-cap biotech stocks to own in 2024, according to Bernstein
- Alnylam price target raised to $220 from $216 at Bernstein
- William Blair sees ATTR-PN market as large enough for two players
